KD-496 CAR T-cells for advanced solid tumors with NKG2DL or CLDN18.2
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new type of immune cell therapy called KD-496, which is a CAR T-cell designed to attack tumors that have NKG2DL or CLDN18.2 markers. It may be an option for people with advanced solid tumors (commonly stomach or pancreatic cancer) who have tried at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced solid tumor (like stomach or pancreatic cancer) that has not responded to at least two standard treatments.
- Your tumor must have at least one of two markers – NKG2DL or CLDN18.2 – confirmed by a tissue test.
- You have at least one tumor that can be measured on scans (like a CT or MRI).
- You are generally able to do daily activities (ECOG score 0 or 1).
- Your heart, lungs, liver, kidneys, and blood counts are working well enough per routine tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell (CAR T) made from healthy donors to fight solid tumors that have not responded to other treatments. It may be an option for people with certain cancers that show a protein called PD-L1.
This trial tests a new type of immune cell therapy (CAR-NKT) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments and whose tumors are CD70-positive.
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
This trial tests a new type of immune cell therapy (CAR T cells) that targets the CD276 protein found on some solid tumors. It is for people whose cancer has not responded to standard treatment or has returned.
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.